Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer
PURPOSE: To develop a predictive test for response and survival following neoadjuvant taxane-anthracycline chemotherapy for HER2-negative invasive breast cancer. METHODS: We developed a microarray-based gene expression test from pre-treatment tumor biopsies (310 patients) to predict favorable outcome based on estrogen receptor (ER) status,pathologic response to chemotherapy, 3-year disease outcomes, and sensitivity to endocrine therapy. Tumors were classified as treatment-sensitive if predicted...
Provenance — who produced it, who reused it
Linked to 40 papers in the literature. Roles are inferred factual signals (who deposited the data vs who reused it), with counts — never a judgement about any author.
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple... 2013 · 731 cites
- <p>Identification of Important Modules and Biomarkers in B... 2020 · 219 cites
- Cancer therapies activate RIG-I-like receptor pathway through en... 2016 · 182 cites
- Unsupervised Clustering of Quantitative Image Phenotypes Reveals... 2017 · 128 cites
- Molecular Characteristics and Metastasis Predictor Genes of Trip... 2012 · 90 cites
- Bioinformatics analysis of the serine and glycine pathway in can... 2014 · 79 cites
- A nine-lncRNA signature predicts distant relapse-free survival o... 2020 · 75 cites
33 further papers cite this accession but reuse could not be confirmed.
Deep data QC
metadata only · no data-level QC for this typeStandardized, field-standard QC computed by touching the data — every metric states how it was obtained
No quantitative QC rubric exists for this data type yet, so it is deliberately left unscored — this is an honest "not applicable", not a poor rating.
measured = computed from the data · extrapolated/reported = derived or from the repository · dq-1.0 · provisional — verify independently